Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Patients with pre-existing autoimmune disorders and cancer considering immune checkpoint inhibitors (ICIs) need to receive balanced information about the benefits and risk of developing immune-related adverse events (irAEs) and flare-ups of their autoimmune disease. To assess the learning needs of p...
Gespeichert in:
Veröffentlicht in: | Cancers 2023-08, Vol.15 (15), p.4004 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 15 |
container_start_page | 4004 |
container_title | Cancers |
container_volume | 15 |
creator | Lopez-Olivo, Maria A Kachira, Johncy J Buni, Maryam Kim, Sang Taek Lu, Huifang Tayar, Jean H Duhon, Gabrielle F Ruiz, Juan I Bingham, 3rd, Clifton O Calabrese, Cassandra Volk, Robert J Suarez-Almazor, Maria E |
description | Patients with pre-existing autoimmune disorders and cancer considering immune checkpoint inhibitors (ICIs) need to receive balanced information about the benefits and risk of developing immune-related adverse events (irAEs) and flare-ups of their autoimmune disease. To assess the learning needs of patients with cancer and pre-existing autoimmune disease regarding ICI treatment, we interviewed 29 patients with autoimmune disease and cancer from a comprehensive cancer center, of whom 20 had received ICI and 9 were candidates to receive ICI at a US Cancer Center. In-depth semi-structured interviews were conducted from August 2021 and January 2022. Interviewee's opinions and preferences about content and information delivery methods were collected. We recorded and transcribed interviews and analyzed them using thematic analysis. Half of the participants were female, and their median (SD) age was 62.9 (±10.9) years. The identified health information needs included the following: (1) information on irAEs and autoimmune disease flare-ups; (2) benefits of ICI; (3) ICI mechanism in the context of autoimmune disease; (4) management of flare-ups; (5) reasons for stopping or modifying cancer or autoimmune disease treatment; (6) likelihood of autoimmune disease progression or organ damage; and (7) lifestyle changes that could help avoid irAEs. Patients who had received ICI and those who had not yet received treatment reported similar needs, although patients who had received ICI had more questions about cancer treatment modifications. Patients also expressed the need to better understand when to contact their provider and how to share information with multiple providers. Most patients wanted to receive information in visual formats for review at home and at their own pace. Patients expressed interest in having educational tools to facilitate shared decision-making with their physicians, and they identified several areas of health information concerning therapy with ICI. They also highlighted the importance of communication among their various providers. |
doi_str_mv | 10.3390/cancers15154004 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10416973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A760514328</galeid><sourcerecordid>A760514328</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-1b4428f1a6fe38fb14e83358a63cf01e0b1fa41aee02fbc8475776a5c0c1c1aa3</originalsourceid><addsrcrecordid>eNptkkFvFCEYhidGY5vaszdD4sXLtDDADHMym23VTTbaGI1HwjAfO9QZWIGp7S_wb8u6tbaNcIDA875fXviK4iXBJ5S2-FQrpyFEwglnGLMnxWGFm6qs65Y9vbc_KI5jvMR5UEqaunleHNCG10KQ9rD4tQYVnHUb9BGgj8gbdKGSBZci-mnTgJZ_iiDleqTQRYDy_NrGtBMs5uTtNM0O0JmNoCKgb4NHiwA7UW97lSCi5NFn0GCvAK328HIA_X3rrUto5Qbb2eRDfFE8M2qMcHy7HhVf351_WX4o15_er5aLdamZaFNJOsYqYYiqDVBhOsJAUMqFqqk2mADuiFGMKABcmU4L1vCmqRXXWBNNlKJHxdu973buJuh1DhrUKLfBTircSK-sfHjj7CA3_koSzEjdNjQ7vLl1CP7HDDHJyUYN46gc-DnKSnBMieC8yejrR-iln4PL-TKV8-SPq_k_aqNGkNYZnwvrnalcNDXmhNFKZOrkP1SePUxWewfG5vMHgtO9QAcfYwBzF5Jguesf-ah_suLV_be54_92C_0NBVHCSg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2848951565</pqid></control><display><type>article</type><title>Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lopez-Olivo, Maria A ; Kachira, Johncy J ; Buni, Maryam ; Kim, Sang Taek ; Lu, Huifang ; Tayar, Jean H ; Duhon, Gabrielle F ; Ruiz, Juan I ; Bingham, 3rd, Clifton O ; Calabrese, Cassandra ; Volk, Robert J ; Suarez-Almazor, Maria E</creator><creatorcontrib>Lopez-Olivo, Maria A ; Kachira, Johncy J ; Buni, Maryam ; Kim, Sang Taek ; Lu, Huifang ; Tayar, Jean H ; Duhon, Gabrielle F ; Ruiz, Juan I ; Bingham, 3rd, Clifton O ; Calabrese, Cassandra ; Volk, Robert J ; Suarez-Almazor, Maria E</creatorcontrib><description>Patients with pre-existing autoimmune disorders and cancer considering immune checkpoint inhibitors (ICIs) need to receive balanced information about the benefits and risk of developing immune-related adverse events (irAEs) and flare-ups of their autoimmune disease. To assess the learning needs of patients with cancer and pre-existing autoimmune disease regarding ICI treatment, we interviewed 29 patients with autoimmune disease and cancer from a comprehensive cancer center, of whom 20 had received ICI and 9 were candidates to receive ICI at a US Cancer Center. In-depth semi-structured interviews were conducted from August 2021 and January 2022. Interviewee's opinions and preferences about content and information delivery methods were collected. We recorded and transcribed interviews and analyzed them using thematic analysis. Half of the participants were female, and their median (SD) age was 62.9 (±10.9) years. The identified health information needs included the following: (1) information on irAEs and autoimmune disease flare-ups; (2) benefits of ICI; (3) ICI mechanism in the context of autoimmune disease; (4) management of flare-ups; (5) reasons for stopping or modifying cancer or autoimmune disease treatment; (6) likelihood of autoimmune disease progression or organ damage; and (7) lifestyle changes that could help avoid irAEs. Patients who had received ICI and those who had not yet received treatment reported similar needs, although patients who had received ICI had more questions about cancer treatment modifications. Patients also expressed the need to better understand when to contact their provider and how to share information with multiple providers. Most patients wanted to receive information in visual formats for review at home and at their own pace. Patients expressed interest in having educational tools to facilitate shared decision-making with their physicians, and they identified several areas of health information concerning therapy with ICI. They also highlighted the importance of communication among their various providers.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15154004</identifier><identifier>PMID: 37568819</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adverse events ; Analysis ; Autoimmune diseases ; Cancer ; Cancer patients ; Cancer therapies ; Care and treatment ; Data collection ; Decision making ; Development and progression ; Disease ; Disease management ; Drug therapy ; Immune checkpoint inhibitors ; Interviews ; Medical research ; Medicine, Experimental ; Melanoma ; Patient education ; Patients ; Qualitative research</subject><ispartof>Cancers, 2023-08, Vol.15 (15), p.4004</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-1b4428f1a6fe38fb14e83358a63cf01e0b1fa41aee02fbc8475776a5c0c1c1aa3</citedby><cites>FETCH-LOGICAL-c489t-1b4428f1a6fe38fb14e83358a63cf01e0b1fa41aee02fbc8475776a5c0c1c1aa3</cites><orcidid>0000-0002-5165-8393 ; 0000-0003-0544-9491</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416973/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416973/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37568819$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lopez-Olivo, Maria A</creatorcontrib><creatorcontrib>Kachira, Johncy J</creatorcontrib><creatorcontrib>Buni, Maryam</creatorcontrib><creatorcontrib>Kim, Sang Taek</creatorcontrib><creatorcontrib>Lu, Huifang</creatorcontrib><creatorcontrib>Tayar, Jean H</creatorcontrib><creatorcontrib>Duhon, Gabrielle F</creatorcontrib><creatorcontrib>Ruiz, Juan I</creatorcontrib><creatorcontrib>Bingham, 3rd, Clifton O</creatorcontrib><creatorcontrib>Calabrese, Cassandra</creatorcontrib><creatorcontrib>Volk, Robert J</creatorcontrib><creatorcontrib>Suarez-Almazor, Maria E</creatorcontrib><title>Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Patients with pre-existing autoimmune disorders and cancer considering immune checkpoint inhibitors (ICIs) need to receive balanced information about the benefits and risk of developing immune-related adverse events (irAEs) and flare-ups of their autoimmune disease. To assess the learning needs of patients with cancer and pre-existing autoimmune disease regarding ICI treatment, we interviewed 29 patients with autoimmune disease and cancer from a comprehensive cancer center, of whom 20 had received ICI and 9 were candidates to receive ICI at a US Cancer Center. In-depth semi-structured interviews were conducted from August 2021 and January 2022. Interviewee's opinions and preferences about content and information delivery methods were collected. We recorded and transcribed interviews and analyzed them using thematic analysis. Half of the participants were female, and their median (SD) age was 62.9 (±10.9) years. The identified health information needs included the following: (1) information on irAEs and autoimmune disease flare-ups; (2) benefits of ICI; (3) ICI mechanism in the context of autoimmune disease; (4) management of flare-ups; (5) reasons for stopping or modifying cancer or autoimmune disease treatment; (6) likelihood of autoimmune disease progression or organ damage; and (7) lifestyle changes that could help avoid irAEs. Patients who had received ICI and those who had not yet received treatment reported similar needs, although patients who had received ICI had more questions about cancer treatment modifications. Patients also expressed the need to better understand when to contact their provider and how to share information with multiple providers. Most patients wanted to receive information in visual formats for review at home and at their own pace. Patients expressed interest in having educational tools to facilitate shared decision-making with their physicians, and they identified several areas of health information concerning therapy with ICI. They also highlighted the importance of communication among their various providers.</description><subject>Adverse events</subject><subject>Analysis</subject><subject>Autoimmune diseases</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Data collection</subject><subject>Decision making</subject><subject>Development and progression</subject><subject>Disease</subject><subject>Disease management</subject><subject>Drug therapy</subject><subject>Immune checkpoint inhibitors</subject><subject>Interviews</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Melanoma</subject><subject>Patient education</subject><subject>Patients</subject><subject>Qualitative research</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkkFvFCEYhidGY5vaszdD4sXLtDDADHMym23VTTbaGI1HwjAfO9QZWIGp7S_wb8u6tbaNcIDA875fXviK4iXBJ5S2-FQrpyFEwglnGLMnxWGFm6qs65Y9vbc_KI5jvMR5UEqaunleHNCG10KQ9rD4tQYVnHUb9BGgj8gbdKGSBZci-mnTgJZ_iiDleqTQRYDy_NrGtBMs5uTtNM0O0JmNoCKgb4NHiwA7UW97lSCi5NFn0GCvAK328HIA_X3rrUto5Qbb2eRDfFE8M2qMcHy7HhVf351_WX4o15_er5aLdamZaFNJOsYqYYiqDVBhOsJAUMqFqqk2mADuiFGMKABcmU4L1vCmqRXXWBNNlKJHxdu973buJuh1DhrUKLfBTircSK-sfHjj7CA3_koSzEjdNjQ7vLl1CP7HDDHJyUYN46gc-DnKSnBMieC8yejrR-iln4PL-TKV8-SPq_k_aqNGkNYZnwvrnalcNDXmhNFKZOrkP1SePUxWewfG5vMHgtO9QAcfYwBzF5Jguesf-ah_suLV_be54_92C_0NBVHCSg</recordid><startdate>20230807</startdate><enddate>20230807</enddate><creator>Lopez-Olivo, Maria A</creator><creator>Kachira, Johncy J</creator><creator>Buni, Maryam</creator><creator>Kim, Sang Taek</creator><creator>Lu, Huifang</creator><creator>Tayar, Jean H</creator><creator>Duhon, Gabrielle F</creator><creator>Ruiz, Juan I</creator><creator>Bingham, 3rd, Clifton O</creator><creator>Calabrese, Cassandra</creator><creator>Volk, Robert J</creator><creator>Suarez-Almazor, Maria E</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5165-8393</orcidid><orcidid>https://orcid.org/0000-0003-0544-9491</orcidid></search><sort><creationdate>20230807</creationdate><title>Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors</title><author>Lopez-Olivo, Maria A ; Kachira, Johncy J ; Buni, Maryam ; Kim, Sang Taek ; Lu, Huifang ; Tayar, Jean H ; Duhon, Gabrielle F ; Ruiz, Juan I ; Bingham, 3rd, Clifton O ; Calabrese, Cassandra ; Volk, Robert J ; Suarez-Almazor, Maria E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-1b4428f1a6fe38fb14e83358a63cf01e0b1fa41aee02fbc8475776a5c0c1c1aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adverse events</topic><topic>Analysis</topic><topic>Autoimmune diseases</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Data collection</topic><topic>Decision making</topic><topic>Development and progression</topic><topic>Disease</topic><topic>Disease management</topic><topic>Drug therapy</topic><topic>Immune checkpoint inhibitors</topic><topic>Interviews</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Melanoma</topic><topic>Patient education</topic><topic>Patients</topic><topic>Qualitative research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lopez-Olivo, Maria A</creatorcontrib><creatorcontrib>Kachira, Johncy J</creatorcontrib><creatorcontrib>Buni, Maryam</creatorcontrib><creatorcontrib>Kim, Sang Taek</creatorcontrib><creatorcontrib>Lu, Huifang</creatorcontrib><creatorcontrib>Tayar, Jean H</creatorcontrib><creatorcontrib>Duhon, Gabrielle F</creatorcontrib><creatorcontrib>Ruiz, Juan I</creatorcontrib><creatorcontrib>Bingham, 3rd, Clifton O</creatorcontrib><creatorcontrib>Calabrese, Cassandra</creatorcontrib><creatorcontrib>Volk, Robert J</creatorcontrib><creatorcontrib>Suarez-Almazor, Maria E</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lopez-Olivo, Maria A</au><au>Kachira, Johncy J</au><au>Buni, Maryam</au><au>Kim, Sang Taek</au><au>Lu, Huifang</au><au>Tayar, Jean H</au><au>Duhon, Gabrielle F</au><au>Ruiz, Juan I</au><au>Bingham, 3rd, Clifton O</au><au>Calabrese, Cassandra</au><au>Volk, Robert J</au><au>Suarez-Almazor, Maria E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-08-07</date><risdate>2023</risdate><volume>15</volume><issue>15</issue><spage>4004</spage><pages>4004-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Patients with pre-existing autoimmune disorders and cancer considering immune checkpoint inhibitors (ICIs) need to receive balanced information about the benefits and risk of developing immune-related adverse events (irAEs) and flare-ups of their autoimmune disease. To assess the learning needs of patients with cancer and pre-existing autoimmune disease regarding ICI treatment, we interviewed 29 patients with autoimmune disease and cancer from a comprehensive cancer center, of whom 20 had received ICI and 9 were candidates to receive ICI at a US Cancer Center. In-depth semi-structured interviews were conducted from August 2021 and January 2022. Interviewee's opinions and preferences about content and information delivery methods were collected. We recorded and transcribed interviews and analyzed them using thematic analysis. Half of the participants were female, and their median (SD) age was 62.9 (±10.9) years. The identified health information needs included the following: (1) information on irAEs and autoimmune disease flare-ups; (2) benefits of ICI; (3) ICI mechanism in the context of autoimmune disease; (4) management of flare-ups; (5) reasons for stopping or modifying cancer or autoimmune disease treatment; (6) likelihood of autoimmune disease progression or organ damage; and (7) lifestyle changes that could help avoid irAEs. Patients who had received ICI and those who had not yet received treatment reported similar needs, although patients who had received ICI had more questions about cancer treatment modifications. Patients also expressed the need to better understand when to contact their provider and how to share information with multiple providers. Most patients wanted to receive information in visual formats for review at home and at their own pace. Patients expressed interest in having educational tools to facilitate shared decision-making with their physicians, and they identified several areas of health information concerning therapy with ICI. They also highlighted the importance of communication among their various providers.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37568819</pmid><doi>10.3390/cancers15154004</doi><orcidid>https://orcid.org/0000-0002-5165-8393</orcidid><orcidid>https://orcid.org/0000-0003-0544-9491</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2023-08, Vol.15 (15), p.4004 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10416973 |
source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Adverse events Analysis Autoimmune diseases Cancer Cancer patients Cancer therapies Care and treatment Data collection Decision making Development and progression Disease Disease management Drug therapy Immune checkpoint inhibitors Interviews Medical research Medicine, Experimental Melanoma Patient education Patients Qualitative research |
title | Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T08%3A33%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Learning%20Needs%20of%20Patients%20with%20Cancer%20and%20a%20Pre-Existing%20Autoimmune%20Disease%20Who%20Are%20Candidates%20to%20Receive%20Immune%20Checkpoint%20Inhibitors&rft.jtitle=Cancers&rft.au=Lopez-Olivo,%20Maria%20A&rft.date=2023-08-07&rft.volume=15&rft.issue=15&rft.spage=4004&rft.pages=4004-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15154004&rft_dat=%3Cgale_pubme%3EA760514328%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2848951565&rft_id=info:pmid/37568819&rft_galeid=A760514328&rfr_iscdi=true |